Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to Lagier et al.
Khanna S, Button JE, Lombardo MJ, Vulic M, Henn MR, Cook DN, Pomerantz RJ, Hohmann EL. Khanna S, et al. Among authors: henn mr. J Infect Dis. 2017 Jan 1;215(1):162-164. doi: 10.1093/infdis/jiw490. Epub 2016 Oct 20. J Infect Dis. 2017. PMID: 28077592 No abstract available.
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
McGovern BH, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, O'Brien EJ, Desjardins CA, Bernardo P, Wortman JR, Lombardo MJ, Litcofsky KD, Winkler JA, McChalicher CWJ, Li SS, Tomlinson AD, Nandakumar M, Cook DN, Pomerantz RJ, Auninš JG, Trucksis M. McGovern BH, et al. Among authors: henn mr. Clin Infect Dis. 2021 Jun 15;72(12):2132-2140. doi: 10.1093/cid/ciaa387. Clin Infect Dis. 2021. PMID: 32255488 Free PMC article. Clinical Trial.
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson AD, Cook DN, Pomerantz RJ, Misra BK, Auninš JG, Trucksis M. Henn MR, et al. Gastroenterology. 2021 Jan;160(1):115-127.e30. doi: 10.1053/j.gastro.2020.07.048. Epub 2020 Aug 4. Gastroenterology. 2021. PMID: 32763240 Free PMC article. Clinical Trial.
Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection.
Normington C, Moura IB, Bryant JA, Ewin DJ, Clark EV, Kettle MJ, Harris HC, Spittal W, Davis G, Henn MR, Ford CB, Wilcox MH, Buckley AM. Normington C, et al. Among authors: henn mr. NPJ Biofilms Microbiomes. 2021 Feb 5;7(1):16. doi: 10.1038/s41522-021-00184-w. NPJ Biofilms Microbiomes. 2021. PMID: 33547298 Free PMC article.
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft CS, Cohen SH, Berenson CS, Korman LY, Ford CB, Litcofsky KD, Lombardo MJ, Wortman JR, Wu H, Auniņš JG, McChalicher CWJ, Winkler JA, McGovern BH, Trucksis M, Henn MR, von Moltke L. Feuerstadt P, et al. Among authors: henn mr. N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516. N Engl J Med. 2022. PMID: 35045228 Clinical Trial.
Intervention strategies for microbial therapeutics in cancer immunotherapy.
Gopalakrishnan V, Weiner B, Ford CB, Sellman BR, Hammond SA, Freeman DJ, Dennis P, Soria JC, Wortman JR, Henn MR. Gopalakrishnan V, et al. Among authors: henn mr. Immunooncol Technol. 2020 May 20;6:9-17. doi: 10.1016/j.iotech.2020.05.001. eCollection 2020 Jun. Immunooncol Technol. 2020. PMID: 35757236 Free PMC article. Review.
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI).
Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, Hasson BR, Fonte AT, McChalicher C, Ege DS, Bryant JA, Straub TJ, Ford CB, Henn MR, Wang EEL, von Moltke L, Wilcox MH. Khanna S, et al. Among authors: henn mr. Antibiotics (Basel). 2022 Sep 10;11(9):1234. doi: 10.3390/antibiotics11091234. Antibiotics (Basel). 2022. PMID: 36140013 Free PMC article. Review.
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.
Glitza IC, Seo YD, Spencer CN, Wortman JR, Burton EM, Alayli FA, Loo CP, Gautam S, Damania A, Densmore J, Fairchild J, Cabanski CR, Wong MC, Peterson CB, Weiner B, Hicks N, Auniņš JG, McChalicher C, Walsh E, Tetzlaff MT, Hamid O, Ott PA, Boland GM, Sullivan RJ, Grossmann KF, Ajami NJ, LaVallee T, Henn MR, Tawbi HA, Wargo JA. Glitza IC, et al. Among authors: henn mr. Cancer Discov. 2024 Apr 4:OF1-OF15. doi: 10.1158/2159-8290.CD-24-0066. Online ahead of print. Cancer Discov. 2024. PMID: 38588588
71 results